VikramKChandMD

PubMed

• 21 citations
  NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
  Gilberto de Castro Jr, Naiyer A Rizvi, Peter Schmid, Konstantinos Syrigos, Claudio Martin, Nobuyuki Yamamoto, Ying Cheng, Vladimir Moiseyenko, Yvonne Summers, Ihor Vyn...> ;Journal of Thoracic Oncology. 2023 Jan 1
• 9 citations
  Curative-Intent Treatment with Durvalumab in Early-Stage Cancers.
  Giovanni Melillo, Vikram Chand, Alejandro Javier Yovine, Ashok K. Gupta, Cristian Massacesi> ;Advances in Therapy. 2021 Apr 21
• 54 citations
  A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
  Han Si, M. Kuziora, Katie Quinn, Elena Helman, Jiabu Ye, F. Liu, U. Scheuring, Solange Peters, Naiyer A. Rizvi, Philip Z Brohawn, Koustubh Ranade, Brandon Higgs, Kimbe...> ;Clinical Cancer Research. 2021 Mar 15
• 383 citations
  Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinic...
  Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Michel M. van den Heuvel, M. Cobo, David Vicente, Alexey Smolin, Vladimi...> ;JAMA Oncology. 2020 May 1
• 274 citations
  Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
  Mary L. Disis, Matthew H. Taylor, Karen Kelly, J. Thaddeus Beck, Michael S. Gordon, Kathleen M. Moore, Manish R. Patel, Jorge Chaves, Haeseong Park, Alain C. Mita, Eri...> ;JAMA Oncology. 2019 Mar 1
• 61 citations
  Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results f...
  Hyun Cheol Chung, Hendrik Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do Youn Oh, Lucjan Wyrwicz, Yoon-Koo Kang, Keun Wook Lee, Jeffrey R. Infante, Sung Sook Lee, M. Ma...> ;Journal for Immunotherapy of Cancer. 2019 Feb 4
• 102 citations
  Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
  Christophe Le Tourneau, Christopher J. Hoimes, Corrine Zarwan, Deborah J. Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, Subramanian Hariharan, Anja von Heydebrec...> ;Journal for Immunotherapy of Cancer. 2018 Oct 22
• 63 citations
  Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
  Julien Taieb, Markus Moehler, Narikazu Boku, Jaffer A. Ajani, Eduardo Yañez Ruiz, Min Hee Ryu, Silke Guenther, Vikram Chand, Yung-Jue Bang> ;Cancer Treatment Reviews. 2018 Apr 22
• 14 citations
  Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired ...
  Leora Horn, Scott N. Gettinger, D. Ross Camidge, Egbert F. Smit, Yelena Y. Janjigian, Vincent A. Miller, William Pao, Matthias Freiwald, Jean Fan, Bushi Wang, Vikram K...> ;Lung Cancer. 2017 Nov 1
• 304 citations
  Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phas...
  Jean-Charles Soria, Enriqueta Felip, Manuel Cobo, Shun Lu, Konstantinos N. Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Dolores Isla, Salih Zeki ...> ;The Lancet. Oncology. 2015 Aug 1
• 70 citations
  Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
  Jacques De Greve, Teresa Moran, Marie-Pascale Graas, Daniella Galdermans, Peter Vuylsteke, Jean-Luc Canon, Denis Schallier, Lore Decoster, Erik Teugels, Dan Massey, Vi...> ;Lung Cancer. 2015 Apr 1
• 303 citations
  Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
  Yelena Y. Janjigian, Egbert F. Smit, Harry J.M. Groen, Leora Horn, Scott N. Gettinger, D. Ross Camidge, Gregory J. Riely, Bushi Wang, Yali Fu, Vikram K. Chand, Vincent...> ;Cancer Discovery. 2014 Sep 1
• 6 citations
  A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors
  Quincy Chu, Randeep Sangha, Sebastien J. Hotte, Gwen Sergenson, David Schnell, Vikram K. Chand, Hal W. Hirte> ;Investigational New Drugs. 2014 Jul 19
• 16 citations
  Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
  Eunice L. Kwak, Geoffrey I. Shapiro, Seth M. Cohen, Heinz-Josef Lenz, Wen-Fang Cheng, Wu Chou Su, Meghan Robohn, Florence Le Maulf, Maximilian T. Lobmeyer, Vikram K. C...> ;Cancer. 2013 Aug 15
• 13 citations
  Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
  Vikram K. Chand, Brian K. Link, Justine M. Ritchie, Mary Shannon, James E. Wooldridge> ;Leukemia & Lymphoma. 2006 Apr 1
• Join now to see all